AI Terminal
DBV Technologies
Report Publication Announcement • Nov 5, 2019
1248_iss_2019-11-05_65aa67b2-b8ad-4e58-ab9e-79df2dd2dfd4.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
DBV Technologies to Present at the Stifel 2019 Healthcare Conference
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Kevin Trapp, Chief Commercial Officer, will present at the Stifel 2019 Healthcare Conference in New York, NY, on Wednesday, November 20, at 8:00 am EST.
A live webcast of the presentation will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay will be available approximately 15 minutes after the event for 90 days.
About DBV Technologies
DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 [email protected]
DBV Media Contact
Joe Becker VP, Global Corporate Communications +1 646-650-3912 [email protected]